216571-44-7Relevant academic research and scientific papers
Methods of treating hepatitis delta virus infection with beta-l-2'-deoxy-nucleosides
-
, (2008/06/13)
A method and composition for treating a host infected with hepatitis D comprising administering an effective hepatitis D treatment amount of a described 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof.
β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
-
, (2008/06/13)
This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2''-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2''-deoxy-β-L-erythro-pentofuranonucleoside has the formula: STR1wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2''-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2''-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.
β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
-
, (2008/06/13)
This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.
A new and convenient approach for the synthesis of rffio- and 2′-deoxyrffio-p-l-furanonucleosides starting from β-l-xylofuranonucleosides
Boudou
, p. 607 - 609 (2007/10/03)
Ribo- and 2′-deoxyribo-β-L-ruranosyladenine have been synthesized. Although these compounds have been already reported in the literature, it seemed to us that a more convenient approach for their synthesis deserved to be developed. Intramolecular substitution as well as Mitsunobu reaction were used to invert the configuration of carbon 3′ of starting β-L-xylofuranosyl intermediates. Copyright
Unnatural β-L-enantiomers of nucleoside analogues as potent anti- hepatitis B virus agents
Gosselin,Boudou,Griffon,Pavia,Pierra,Imbach,Faraj,Sommadossi
, p. 1731 - 1738 (2007/10/03)
Several 2'- or 3'- substituted 2',3'-dideoxy-β-L-nucleosides bearing adenine as the base were stereospecifically synthesized and their antiviral properties examined. Two of them, namely 2'-azido- and 3'-azido-2',3'- dideoxy-β-L-adenosine (2'-N3
